MX2017011851A - Composiciones de acido nicotinico ribosido o de nicotinamida ribosido, derivados reducidos de los mismos, y su uso. - Google Patents
Composiciones de acido nicotinico ribosido o de nicotinamida ribosido, derivados reducidos de los mismos, y su uso.Info
- Publication number
- MX2017011851A MX2017011851A MX2017011851A MX2017011851A MX2017011851A MX 2017011851 A MX2017011851 A MX 2017011851A MX 2017011851 A MX2017011851 A MX 2017011851A MX 2017011851 A MX2017011851 A MX 2017011851A MX 2017011851 A MX2017011851 A MX 2017011851A
- Authority
- MX
- Mexico
- Prior art keywords
- riboside
- nicotinamide
- nar
- derivatives
- nicotinic acid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/048—Pyridine radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/673—Vitamin B group
- A61K8/675—Vitamin B3 or vitamin B3 active, e.g. nicotinamide, nicotinic acid, nicotinyl aldehyde
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/18—Antioxidants, e.g. antiradicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/004—Aftersun preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/007—Preparations for dry skin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Birds (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Toxicology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
- Saccharide Compounds (AREA)
- Artificial Fish Reefs (AREA)
Abstract
Se proporcionan derivados de ácido nicotínico ribósido (NAR), nicotinamida ribósido (NR) , y NAR y NR reducidos, incluyendo ácido 1- (2',3',Y-triacetil-beta-D-ribofuranosil)- 1,4-dihidronicotinico (4a), y composiciones que los contienen, y/o formas de derivados reducidos de nicotinamida ribósido, incluyendo 1-(2',3',5'-triacetil-beta-D-ribofuranosil)-1,4- nicotinamida (2), para use en el cuidado del tratamiento de la piel y afecciones de la piel. En algunas realizaciones, la invención se refiere a composiciones farmacéuticas y a composiciones cosméticas que contienen uno o más derivados de NR, NAR, NRH, o NARH, o profármacos o sales de los mismos. En realizaciones adicionales, la invención se refiere a métodos para usar uno o más derivados de NR, NAR, NRH, o NARH, o profármacos, solvatos, o sales de los mismos, para promover el incremento de niveles intracelulares de nicotinamida adenina dinucleótido (NAD+) en células y tejidos para mejorar la supervivencia de células y tejidos y la salud general de células y tejidos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562133845P | 2015-03-16 | 2015-03-16 | |
| PCT/US2016/022682 WO2016149395A1 (en) | 2015-03-16 | 2016-03-16 | Nicotinic acid riboside or nicotinamide riboside compositions, reduced derivatives thereof, and the use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2017011851A true MX2017011851A (es) | 2018-04-11 |
Family
ID=56920324
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017011851A MX2017011851A (es) | 2015-03-16 | 2016-03-16 | Composiciones de acido nicotinico ribosido o de nicotinamida ribosido, derivados reducidos de los mismos, y su uso. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US10280190B2 (es) |
| EP (1) | EP3271370B1 (es) |
| JP (2) | JP7244163B2 (es) |
| KR (1) | KR102426320B1 (es) |
| CN (2) | CN107531738B (es) |
| AU (1) | AU2016233247B2 (es) |
| BR (1) | BR112017019696A2 (es) |
| CA (1) | CA2979057C (es) |
| HK (1) | HK1248240A1 (es) |
| MX (1) | MX2017011851A (es) |
| NZ (1) | NZ735411A (es) |
| WO (1) | WO2016149395A1 (es) |
| ZA (1) | ZA201706918B (es) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2017145692A (ru) | 2015-06-10 | 2019-07-10 | Элизиум Хелт, Инк. | Композиции никотинамида рибозида и птеростильбена и способы лечения заболеваний кожи |
| EP3322419A4 (en) | 2015-07-15 | 2018-08-01 | Cornell University | Syntheses, activities, and methods of use of dihydronicotinamide riboside derivatives |
| CN109640984A (zh) * | 2016-04-20 | 2019-04-16 | 可劳迈戴斯有限公司 | 烟酸核苷或烟酰胺核苷衍生物及其还原的衍生物作为增加nad+的前体的用途 |
| GB2553001A (en) * | 2016-08-19 | 2018-02-21 | The Queen's Univ Of Belfast | Lactone intermediates of nicotinamide riboside and nicotinate riboside |
| WO2018089830A1 (en) | 2016-11-11 | 2018-05-17 | The Queen's University Of Belfast | Efficient and scalable syntheses of nicotinoyl ribosides and reduced nicotinoyl ribosides, modified derivatives thereof, phosphorylated analogs thereof, adenylyl dinucleotide conjugates thereof, and novel crystalline forms thereof |
| MX2019006278A (es) | 2016-11-29 | 2019-08-21 | Univ Iowa Res Found | Uso de precursores de nad para mejorar la salud materna y/o salud de la descendencia. |
| US11071747B2 (en) | 2016-11-29 | 2021-07-27 | University Of Iowa Research Foundation | Use of NAD precursors for breast enhancement |
| SG11201912267SA (en) | 2017-06-19 | 2020-01-30 | Gangadhara Ganapati | Nicotinamide riboside derivatives and their uses |
| CN110283221A (zh) * | 2018-03-19 | 2019-09-27 | 药源药物化学（上海）有限公司 | 杂环化合物的制备和纯化方法 |
| US10654883B2 (en) * | 2018-05-15 | 2020-05-19 | Jumpstart Fertility Pty Ltd | Inorganic salts of nicotinic acid mononucleotide as anti-aging agents |
| EP3794007A1 (en) | 2018-05-18 | 2021-03-24 | Roche Diagnostics GmbH | (thio)nicotinamide ribofuranoside salts and compositions, methods of making, and uses thereof |
| WO2019226755A1 (en) * | 2018-05-22 | 2019-11-28 | Jumpstart Fertility Pty Ltd | Amino acid salts of nicotinic acid ribosides as anti-aging agents |
| KR20210108400A (ko) * | 2018-12-10 | 2021-09-02 | 크로마덱스 아이엔씨. | 니코티노일 리보사이드 및 이의 유도체의 결정질 형태 및 이의 제조 방법 |
| EP3897666A2 (en) | 2018-12-17 | 2021-10-27 | Mitopower LLC | Nicotinyl riboside compounds and their uses |
| WO2020191359A1 (en) * | 2019-03-21 | 2020-09-24 | Fred Hutchinson Cancer Research Center | Cancer combination therapies utilizing a nicotinamide phosphoribosyltransferase inhibitor in combination with a nicotinamide adenine dinucleotide salvage pathway precursor |
| WO2020190703A1 (en) * | 2019-03-21 | 2020-09-24 | Elysium Health, Inc. | Methods for wound treatment |
| MX2022000774A (es) | 2019-07-19 | 2022-05-03 | Biosynth Ag | Metodo para elaborar sales de ribofuranosido de nicotinamida, sales de ribofuranosido de nicotinamida como tal, y usos de las mismas. |
| KR102315139B1 (ko) * | 2019-12-17 | 2021-10-20 | 주식회사 휴메딕스 | 지방아민 컨쥬게이션된 니코틴아미드 리보사이드 유도체 |
| WO2021180739A1 (en) * | 2020-03-09 | 2021-09-16 | Société des Produits Nestlé S.A. | Compositions and methods containing reduced nicotinamide riboside for prevention and treatment of viral and bacterial infections |
| CN111909229B (zh) * | 2020-08-12 | 2023-05-05 | 福建瑞博奥科技有限公司 | 一种β-烟酰胺核糖氯化物的制备方法 |
| GB202107957D0 (en) * | 2021-06-03 | 2021-07-21 | Mitocholine Ltd | Nutritional compositions for skeletal muscle |
| CN115232184B (zh) * | 2021-12-06 | 2024-07-05 | 宁波熙健医药科技有限公司 | 呋喃核糖基吡啶衍生物及其药物组合物和用途 |
| WO2023119230A1 (en) | 2021-12-22 | 2023-06-29 | L'oreal | Coagulation pathway and nicotinamide-adenine dinucleotide pathway modulating compositions and methods of their use |
| AU2023236547A1 (en) * | 2022-03-15 | 2024-08-22 | ChromaDex Inc. | Methods of producing crystalline beta nicotinamide riboside triacetate chloride |
| WO2024050120A2 (en) * | 2022-09-02 | 2024-03-07 | The Regents Of The University Of California | Nicotinamide-riboside and pterostilbene combinations to treat osteoarthritis |
| WO2024118503A1 (en) | 2022-11-28 | 2024-06-06 | Hongene Biotech Corporation | Functionalized n-acetylgalactosamine analogs |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1993008388A1 (en) | 1991-10-18 | 1993-04-29 | Dong Il Whang | Rotary internal combustion engine |
| US5633158A (en) * | 1991-10-23 | 1997-05-27 | Cancer Research Campaign Technology Limited | Bacterial nitroreductase for the reduction of CB 1954 and analogues thereof to a cytotoxic form |
| GB9712370D0 (en) * | 1997-06-14 | 1997-08-13 | Aepact Ltd | Therapeutic systems |
| CA2555675A1 (en) * | 2004-02-10 | 2005-08-25 | Trustees Of Dartmouth College | Nicotinamide riboside kinase compositions and methods for using the same |
| PT3006040T (pt) | 2004-06-04 | 2018-03-28 | Univ Washington | Métodos e composições para o tratamento de neuropatias |
| US20060229265A1 (en) * | 2005-03-30 | 2006-10-12 | Sirtris Pharmaceuticals, Inc. | Nicotinamide riboside and analogues thereof |
| CN101360421B (zh) | 2005-11-18 | 2014-06-18 | 康乃尔研究基金会有限公司 | 烟酰核苷组合物及其使用方法 |
| JP6550370B2 (ja) | 2013-03-15 | 2019-07-24 | ニューサート サイエンシーズ， インコーポレイテッド | 脂質レベルを低下させるロイシンおよびニコチン酸 |
| GB201313465D0 (en) | 2013-07-29 | 2013-09-11 | Queens University Of The Belfast | Methods of preparing nicotinamide riboside and derivatives thereof |
| MX2021009652A (es) | 2013-10-30 | 2022-07-26 | Chromadex Inc | Composiciones de ribosido de nicotinamida para uso topico en el tratamiento de afecciones de la piel. |
| RU2016149767A (ru) * | 2014-06-06 | 2018-07-16 | Глэксосмитклайн Интеллекчуал Проперти (Но.2) Лимитед | Аналоги никотинамидрибозида и фармацевтические композиции и их применение |
| US20160317420A1 (en) * | 2015-05-01 | 2016-11-03 | The Procter & Gamble Company | Method of improving the appearance of skin and compositions therefor |
| EP3322419A4 (en) * | 2015-07-15 | 2018-08-01 | Cornell University | Syntheses, activities, and methods of use of dihydronicotinamide riboside derivatives |
-
2016
- 2016-03-16 JP JP2017548461A patent/JP7244163B2/ja active Active
- 2016-03-16 NZ NZ735411A patent/NZ735411A/en unknown
- 2016-03-16 MX MX2017011851A patent/MX2017011851A/es unknown
- 2016-03-16 KR KR1020177029466A patent/KR102426320B1/ko active IP Right Grant
- 2016-03-16 CN CN201680022370.2A patent/CN107531738B/zh active Active
- 2016-03-16 CN CN202010541644.7A patent/CN111643512A/zh active Pending
- 2016-03-16 US US15/072,121 patent/US10280190B2/en active Active
- 2016-03-16 CA CA2979057A patent/CA2979057C/en active Active
- 2016-03-16 WO PCT/US2016/022682 patent/WO2016149395A1/en active Application Filing
- 2016-03-16 BR BR112017019696A patent/BR112017019696A2/pt not_active Application Discontinuation
- 2016-03-16 AU AU2016233247A patent/AU2016233247B2/en active Active
- 2016-03-16 EP EP16765675.0A patent/EP3271370B1/en active Active
-
2017
- 2017-10-12 ZA ZA2017/06918A patent/ZA201706918B/en unknown
-
2018
- 2018-06-15 HK HK18107794.3A patent/HK1248240A1/zh unknown
-
2020
- 2020-10-22 JP JP2020177461A patent/JP2021020934A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3271370C0 (en) | 2023-06-21 |
| JP2021020934A (ja) | 2021-02-18 |
| AU2016233247B2 (en) | 2020-12-03 |
| HK1248240A1 (zh) | 2018-10-12 |
| KR102426320B1 (ko) | 2022-07-29 |
| EP3271370A4 (en) | 2018-11-21 |
| CN111643512A (zh) | 2020-09-11 |
| ZA201706918B (en) | 2019-01-30 |
| CA2979057C (en) | 2023-01-24 |
| JP2018508543A (ja) | 2018-03-29 |
| EP3271370B1 (en) | 2023-06-21 |
| US20160272668A1 (en) | 2016-09-22 |
| AU2016233247A1 (en) | 2017-09-21 |
| WO2016149395A1 (en) | 2016-09-22 |
| JP7244163B2 (ja) | 2023-03-22 |
| EP3271370A1 (en) | 2018-01-24 |
| CA2979057A1 (en) | 2016-09-22 |
| CN107531738A (zh) | 2018-01-02 |
| US10280190B2 (en) | 2019-05-07 |
| NZ735411A (en) | 2021-07-30 |
| BR112017019696A2 (pt) | 2018-09-04 |
| KR20180004113A (ko) | 2018-01-10 |
| CN107531738B (zh) | 2021-02-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2017011851A (es) | Composiciones de acido nicotinico ribosido o de nicotinamida ribosido, derivados reducidos de los mismos, y su uso. | |
| MX2018001363A (es) | Derivados del mononucleotido de nicotinamida y sus usos. | |
| NZ747693A (en) | Use of nicotinic acid riboside or nicotinamide riboside derivatives, and reduced derivatives thereof, as nad+increasing precursors | |
| MX2016005574A (es) | Composiciones de ribosido de nicotinamida para uso topico en el tratamiento de afecciones de la piel. | |
| PH12020551315A1 (en) | Benzoxazepin oxazolidinone compounds and methods of use | |
| TR201909582T4 (tr) | Pirimido[4,5-b]indol türevleri ve hematopoetik kök hücrelerinin ekspresyonunda bunlarin kullanimi. | |
| MX2019011772A (es) | Expresion transgenica selectiva de tejidos. | |
| PH12018500371A1 (en) | Clinical formulations | |
| UY31305A1 (es) | Derivados de 1,2,4,5-tetrahidro-3h-benzazepinas, su procedimiento de preparacion y las composiciones farmacéuticas que las contienen. | |
| MX356815B (es) | Composiciones y métodos para mejorar el estado bioenergético en células germinales femeninas. | |
| UY31730A (es) | Derivados polisustituidos de 6-heteroaril-imidazo[1,2-a]piridinas, su preparación y su aplicación en terapéutica. | |
| PE20161066A1 (es) | Derivados de piperidinil-indol como inhibidores del factor de complemento b y usos de los mismos | |
| MX369616B (es) | Composiciones cutaneas y metodos para su uso. | |
| UA95105C2 (ru) | Применение производного лактамида для снижения токсичности в препарате, который может соприкасаться с кожей или глазами человека или животного, производные лактамида и способы их получения | |
| MX2015012176A (es) | Metodos de usar zscan4 para rejuvenecer celulas humanas. | |
| PH12014501309A1 (en) | Mammalian fetal pulmonary cells and therapeutic use of same | |
| MX2012007896A (es) | Derivados de piridino-piridinonas arilsulfonamidas, su preparacion y su uso en terapeutica. | |
| CL2020000019A1 (es) | Agentes de iarn para la inhibición de la expresión de alfa-enac y métodos de uso. | |
| MX2016015256A (es) | Composicion de aclaramiento topica y metodos de uso de la misma. | |
| CL2009001267A1 (es) | Compuestos derivados de triciclos nitrogenados, con actividad antibacteriana; procedimiento de preparacion; composicion farmceutica que los comprende; para el tratamiento de la tuberculosis. | |
| WO2006072809A8 (en) | Formulations that optimize intracellular concentration of nicotinamide adenine (nad+) and methods of use to protect cells and treat diseases and conditions | |
| PH12015501643B1 (en) | Methods of use of phenoxypropylamine compounds to treat depression | |
| TW200738677A (en) | Nitro-substituted hydroxyindoles, their use as inhibitors of phosphodiesterase 4, and processes for preparing them | |
| MX2022003997A (es) | Derivados de androstano con actividad como estimuladores puros o predominantemente puros de serca2a para el tratamiento de la insuficiencia cardiaca. | |
| MX2016014261A (es) | Uso de acido 1,3-propandisulfonico o sales farmaceuticamente aceptables del mismo para el tratamiento de sarcoidosis. |